Immutep (ASX:IMM) share price slips amid trial safety update

Initial study results look promising but investors don’t appear too excited…
The post Immutep (ASX:IMM) share price slips amid trial safety update appeared first on The Motley Fool Australia. –

The Immutep Ltd (ASX: IMM) share price is in the red this morning, down 1.05% at the time of writing to 47 cents.

The biotech company is developing LAG-3 related immunotherapy treatments for patients with cancer and autoimmune disease.

Below, we take a look at the latest clinical study update from the ASX medical share.

What study update was announced?

The Immutep share price is falling after the company reported good safety results from the first 5 patients in its INSIGHT-003 study.

INSIGHT-003, according to the release, is an investigator-initiated study conducted by the Institute of Clinical Cancer Research IKF at Krankenhaus Nordwest in Frankfurt, Germany.

The study is evaluating the triple combination therapy of eftilagimod alpha (efti) given alongside chemotherapy and anti-PD-1 therapy.

Immutep said it had not observed any additional safety signals in the study from the first 5 patients given the triple therapy.

However, the news does not appear to have excited investors, judging by the Immutep share price this morning.

Commenting on the results, lead investigator Salah-Eddin Al-Batran of the Institute of Clinical Cancer Research IKF said:

The INSIGHT-003 study has commenced well. We are very pleased with the safety of the triple combination so far and all patients are still participating in the study. This is important as it is the first time patients have received a triple combination therapy with efti. Patient recruitment is advancing in line with our projections.

INSIGHT-003 expects to recruit up to 20 patients with a range of solid tumours. The trial is meant to assess the safety, tolerability, and initial efficacy of the triple combination treatment.

Additionally, Immutep intends to release further results from the ongoing study in 2022 — results shareholders will be watching closely.

Immutep share price snapshot

The Immutep share price is up 69% over the past year, and 12% this year to date. By comparison, the All Ordinaries Index (ASX: XAO) is up around 10% over both those timeframes.

Over the past month, Immutep shares are down around 20%.

The post Immutep (ASX:IMM) share price slips amid trial safety update appeared first on The Motley Fool Australia.

Should you invest $1,000 in Immutep right now?

Before you consider Immutep, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Immutep wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

More reading

Why Afterpay, Immutep, Pushpay, and Vulcan shares are falling

Immutep (ASX:IMM) share price slides 20% despite latest trial results

The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!